CONNECT WITH US
HealthTech

HealthTech

ASN: Fruits and vegetables improve outcomes in stage 3 chronic kidney disease

Medical Xpress logo

Published on

Add as a preferred source on Google
ASN: Fruits and vegetables improve outcomes in stage 3 chronic kidney disease

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

For patients with stage 3 chronic kidney disease (CKD), receiving fruits and vegetables (F&V) is associated with better clinical outcomes than standard treatment with sodium bicarbonate (NaHCO₃ [HCO₃]) or usual care, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held from Oct. 21 to 25 in Denver.

Nimrit Goraya, M.D., of Baylor Scott and White Health in Temple, Texas, and colleagues compared clinical outcomes in patients with CKD stage 3 and metabolic acidosis treated with F&V or HCO₃ compared to usual care. Participants were randomly assigned to F&V to reduce dietary acid by half, oral HCO₃ (0.3 mmol/kg/day), or usual care receiving standard CKD treatment (36 participants in each group) and were followed for 10 years.

The researchers found there were 115 hospitalizations and 166 emergency department visits (EDV) during follow-up, and 34 patients progressed to kidney replacement therapy (KRT). F&V was associated with fewer hospitalizations (14 versus 64), fewer EDVs (20 versus 88), and less progression to KRT (four versus 16) compared with usual care. Regarding hospitalization, EDVs, and progression to KRT, no difference was seen between HCO₃ and usual care.

There was no difference observed between the groups in total 10-year costs; treatment costs for F&V, but not HCO₃, increased more slowly than those for usual care. 16% lower for F&V than HCO₃.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.